ZIM
TCRT icon

Zacks Investment Management’s Alaunos Therapeutics TCRT Stock Holding History

Zacks Investment Management’s Portfolio TCRT Stock Details TCRT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-297
Closed -$77K – 659
2022
Q3 		$77K Buy
+297
New +$86.3K ﹤0.01% 556
2015
Q4 		– Sell
-347
Closed -$469K – 650
2015
Q3 		$469K Buy
347
+36
+12% +$59.4K 0.02% 440
2015
Q2 		$560K Buy
+311
New +$483K 0.02% 421
2014
Q2 		– Sell
-356
Closed -$244K – 746
2014
Q1 		$244K Buy
+356
New +$238K 0.01% 583

Other funds holding TCRT

DCM
Discovery Capital Management South Norwalk, Connecticut $1.92B AUM 218.96% 1-Year Est. Return
MP
MSD Partners New York $82.3M AUM 15.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AC
Addison Capital Conshohocken, Pennsylvania $562M AUM 18.57% 1-Year Est. Return
SGCA
Steel Grove Capital Advisors Memphis, Tennessee $949M AUM 23.78% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Two Sigma Advisers
Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Zacks Investment Management's TCRT Position: Q4 2022 in Review

Zacks Investment Management sold out of Alaunos Therapeutics (TCRT) in Q4 2022, closing a stake of 297 shares — an estimated $77K sold.

Zacks Investment Management first reported a position in TCRT in Q1 2014 and held it in 4 quarters. The position peaked at $560K in Q2 2015. 122 funds tracked by Wall St. Rank hold TCRT as of Q4 2022.

  • Zacks Investment Management reported no remaining Alaunos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • Zacks Investment Management sold 297 Alaunos Therapeutics shares in Q4 2022, an estimated $77K.
  • Zacks Investment Management first reported a position in Alaunos Therapeutics in Q1 2014 and held it in 4 quarters.
  • Zacks Investment Management's Alaunos Therapeutics position peaked at $560K in Q2 2015.
  • 122 funds tracked by Wall St. Rank held Alaunos Therapeutics as of Q4 2022.

Based on Zacks Investment Management's 13F filing for Q4 2022, filed 14 Feb 2023.